PURE Bioscience Appoints Peter C. Wulff as Chief Financial Officer

  PURE Bioscience Appoints Peter C. Wulff as Chief Financial Officer

Business Wire

SAN DIEGO -- November 08, 2012

PURE Bioscience, Inc. (NASDAQ: PURE), the creator of the patented silver
dihydrogen citrate (SDC) antimicrobial, today announced it has named Peter C.
Wulff as Chief Financial Officer, effective November 5, 2012. Mr. Wulff has 25
years of financial and operating management experience, including more than 12
years as a senior-level executive in the life science industry. Most recently
Mr. Wulff served as Chief Financial Officer, Vice President, Treasurer and
Senior Vice President, Strategic Initiatives for Alphatec Holdings, Inc.
(NASDAQ: ATEC) and its subsidiary, Alphatec Spine, Inc., a developer and
manufacturer of spinal implant products.

Michael L. Krall, President and CEO of PURE Bioscience, said, “Peter has a
proven ability to manage rapid growth and oversee the development of
successful new products and technologies. We are confident that his expertise
will be of immediate benefit across our business, including optimizing our
many current opportunities and creating new growth initiatives.”

Earlier in his career Mr. Wulff served as Executive Vice President and Chief
Financial Officer for Artes Medical, Inc., where he managed the company’s
initial public offering and introduction of FDA-approved products. He also was
Chief Financial Officer for CryoCor, Inc., a medical device company; and Chief
Financial Officer and Treasurer of Natural Alternatives International, Inc., a
manufacturer of nutritional products.

Mr. Wulff received both a Bachelor’s degree in Economics and Germanic
Languages and a Master’s in Business Administration in Finance from Indiana
University.

As an inducement material to Mr. Wulff entering into employment with PURE,
PURE has agreed, subject to the approval of PURE’s Compensation Committee, to
grant to Mr. Wulff an option to purchase up to 50,000 shares of its common
stock with an exercise price equal to the fair market value of PURE’s common
stock on the grant date of the option, which will be the date of the
Compensation Committee’s approval of the option grant. The option will have a
term of 10 years and will generally be forfeited if not exercised before the
expiration of that term, or, if earlier, the 120th day after the termination
of Mr. Wulff’s employment with us (subject to certain exceptions). The shares
subject to the option will vest in four equal annual installments on each
yearly anniversary of the commencement date of Mr. Wulff’s employment with
PURE, in each case subject to Mr. Wulff’s continued service with PURE through
such vesting date. The option will be granted outside of PURE’s 2007 Equity
Incentive Plan but will be subject to terms substantially similar to those of
non-qualified stock options granted under such plan. This description of the
inducement option grant to Mr. Wulff is in satisfaction of the disclosure
requirements set forth in NASDAQ Listing Rule 5635(c)(4).

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience
products that provide solutions to numerous global health challenges,
including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity
bioscience technologies, including its silver dihydrogen citrate-based
antimicrobials, represent innovative advances in diverse markets and lead
today’s global trend toward industry and consumer use of “green” products
while providing competitive advantages in efficacy and safety. Patented SDC is
an electrolytically generated source of stabilized ionic silver, which
formulates well with other compounds. As a platform technology, SDC is
distinguished from competitors in the marketplace because of its superior
efficacy, reduced toxicity and the inability of bacteria to form a resistance
to it. PURE is headquartered in El Cajon, California (San Diego metropolitan
area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute “forward-looking”
statements, sometimes containing the words “believe,” “estimate,” “project,”
“expect” or similar expressions. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements inherently involve risks and uncertainties
that could cause actual results to differ materially from the forward-looking
statements. Factors that could cause or contribute to such differences
include, without limitation, disruptions to Pure’s business and operations or
disagreements regarding its strategic goals and models resulting from changes
in the composition of its management team; Pure’s ability to attract and
retain skilled personnel; Pure’s cash position and liquidity requirements;
acceptance of the Pure's current and future products and services in the
marketplace; the ability of Pure to develop effective new products and receive
regulatory approvals of such products; and other risks detailed in Pure's
filings with the Securities and Exchange Commission. By making these
forward-looking statements, Pure undertakes no obligation to update these
statements for revisions or changes after the date of this release.

Contact:

PURE Bioscience Investor Contact:
LHA
Don Markley, Senior Vice President
(310) 691-7100
dmarkley@lhai.com
 
Press spacebar to pause and continue. Press esc to stop.